Biotechnology company Moderna (NASDAQ: MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.
Moderna beat analysts’ revenue expectations by 48.8% last quarter, reporting revenues of $1.86 billion, up 1.7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations.
Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Moderna’s revenue to decline 65.6% year on year to $965.6 million, a further deceleration from the 44.7% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$2.73 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Moderna has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Moderna’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Gilead Sciences delivered year-on-year revenue growth of 6.4%, beating analysts’ expectations by 6.3%, and Vertex Pharmaceuticals reported revenues up 15.7%, topping estimates by 4.9%. Gilead Sciences traded up 7.5% following the results while Vertex Pharmaceuticals was down 3%.
Read our full analysis of Gilead Sciences’s results here and Vertex Pharmaceuticals’s results here.
Investors in the therapeutics segment have had steady hands going into earnings, with share prices flat over the last month. Moderna is down 11.8% during the same time and is heading into earnings with an average analyst price target of $62.01 (compared to the current share price of $30.71).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
